Lucid Lane, Flow Neuroscience, Innomost
Real Time Medical Systems Raises $20M In Series C Funding
Real Time Medical Systems, a Baltimore-based provider of a healthcare interventional analytics solution, closed a $20m Series C funding.
The round was led by BASE Capital and SunBridge Capital.
The company intends to use the funds to advance its interventional analytics platform and further accelerate its market growth.
Led by Joan Neuscheler, Chief Executive Officer, Real Time provides an interventional analytics platform that enhances care coordination and clinical decision making through EHR data interoperability between post-acute care (PAC) facilities and health systems, ACOs, and payers. Using live clinical alerts coupled with recommended interventions, Real Time enables care teams to reduce hospital admission rates, detect early signs of infectious diseases, and improve patient outcomes throughout the continuum of care.
Real Time Medical Systems Raises $20M In Series C Funding
Real Time Medical Systems, a Baltimore-based provider of a healthcare interventional analytics solution, closed a $20m Series C funding
Smile CDR Raises $20M in Series A Funding
Smile CDR, Inc., a Toronto, Canada-based health data storage and integration company, closed a $20m Series A funding round.
The round was led by 30 North Group and UPMC Enterprises.
The company intends to use the funds to expand operations and its business reach.
Led by Duncan Weatherston, Chief Executive Officer, Smile CDR offers a suite of services that allow health systems, payers and hospitals to meet U.S. health information interoperability standards securely. Its data and integration platform includes a complete clinical data repository (CDR) built around the Health Level Seven (HL7®) Fast Healthcare Interoperability Resources (FHIR®) standard used for storing health records and supports all FHIR Resources.
Smile CDR Raises $20M in Series A Funding | FinSMEs
Smile CDR, Inc., a Toronto, Canada-based health data storage and integration company, closed a $20m Series A funding round
SeQure Dx Raises $17.5M in Series A Funding
SeQure Dx, a Waltham, Mass.-based gene-editing diagnostics company, raised $17.5m in Series A funding.
The round was led by RiverVest Venture Partners and Mass General Brigham Ventures with participation from Digitalis Ventures, Casdin Capital, KdT Ventures, Bold Capital Partners and Alexandria Venture Investments.
Led by Ellen Sheets, MD, MBA, CEO, The company intends to use the funds to establish a full-service laboratory providing off-target gene-editing analysis for use in drug development, clinical trials and patient evaluation prior to therapy.
SeQure Dx Raises $17.5M in Series A Funding | FinSMEs
SeQure Dx, a Waltham, Mass.-based gene-editing diagnostics company, raised $17.5m in Series A funding
Lucid Lane Raises $16M in Series A Funding
Lucid Lane, a Los Altos, Calif.-based telehealth solution for people with medication dependence and substance-use disorders, raised $16m in Series A funding.
The round was led by Accel with participation from Battery Ventures, AME Cloud Ventures, Morado Ventures and strategic angel investors. In conjunction with the funding, Eric Wolford, Partner at Accel, has joined the Lucid Lane board of directors.
The company intends to use the funds to continue to expand operations, development efforts and its business reach.
Led by Adnan Asar, co-founder and CEO, Lucid Lane uses data-driven personalized health planning, real-time interventions, daily coach-based support and daily on-going access to therapist support to support people with medication dependence and substance-use disorder. The solution is a core set of technologies and services that provide ongoing measurement and monitoring, personalized treatment planning and timely interventions.
Lucid Lane Raises $16M in Series A Funding
Lucid Lane, a Los Altos, Calif.-based telehealth solution for people with medication dependence and substance-use disorders, raised $16m in Series A funding
This Swiss biotech startup is developing a new Covid-19 vaccine; raises €6.6M to prepare clinical trials
Recently, the biotech startup RocketVax AG has raised CHF 7.2M (approx €6.6M) funding in a Series A round to fund the pre-clinical development of its Covid-19 vaccine.
The funds will be used to prepare clinical trials of RocketVax’s Covid-19 vaccine.
Based out of Basel, Switzerland, RocketVax AG is a company that aims to develop novel vaccines with its proprietary molecular biology and chemical technology. The chemical approach is based on the core technology of Gigabases, which has provided synthetically produced DNA.
This Swiss biotech startup is developing a new Covid-19 vaccine; raises €6.6M to prepare clinical trials | Silicon Canals
RocketVax AG, a Swiss startup that aims to develop novel vaccines for COVID-19 with its proprietary molecular biology and chemical technology bags €6.6M.
Eyevensys Raises $12M in Series B+ Funding
Eyevensys, a Paris, France and Cambridge MA-based biotechnology company developing non-viral gene therapies for ophthalmic diseases, raised $12M in Series B+ funding.
The round was led by Korea Investment Partners.
The company intends to use the funds for the development of its EYS809 program for the treatment of wet age-related macular degeneration (AMD), a chronic eye disorder that causes blurred vision or a blind spot in the eye. Additionally, Eyevensys will advance its EYS611 program targeting geographic atrophy (GA) and retinitis pigmentosa.
Founded in 2008 and led by Dr. Patricia Zilliox, Eyevensys is advancing a non-viral gene therapy ocular drug delivery platform that uses an Electrotransfection System to deliver DNA plasmids encoding therapeutic proteins into the ciliary muscle to sustainably treat major eye diseases.
Eyevensys Raises $12M in Series B+ Funding | FinSMEs
Eyevensys, a Paris, France and Cambridge MA-based biotechnology company developing non-viral gene therapies for ophthalmic diseases, raised $12M in Series B+ funding
Swedish startup Flow Neuroscience raises over €7.9 million to make its self-managed medical device available globally
Today, Swedish medtech startup Flow Neuroscience, developer of a medically approved transcranial direct current stimulation (tDCS) device and behavioural therapy app for depression, has raised over €7.9 million in Series A funding.
The oversubscribed round was led by Khosla Ventures, CSS group through Swiss Health Ventures and Zühlke Ventures.
The fresh capital will support the development of Flow’s depression treatment to be more patient-specific. It will also accelerate the development of non-pharmaceutical self-managed solutions for other mental health disorders, such as anxiety. The new funding round will allow the company to strengthen its offering to the European market, as well as preparing for US market entry through clinical trials and FDA approval.
Founded in 2016 by clinical psychologist Daniel Månsson, and neuroscientist Erik Rehn, the Malmö-based startup aims to fill the treatment gap between medication and therapy, with the Flow headset solution, being a drug-free and medically approved, at-home tDCS depression treatment.
Swedish startup Flow Neuroscience raises over €7.9 million to make its self-managed medical device available globally | EU-Startups
Today, Swedish medtech startup Flow Neuroscience, developer of a medically approved transcranial direct current stimulation (tDCS) device and behavioural
Innomost Raises €5M in Funding
Innomost, a Helsinki, Finland-based startup that upcycles valuable birch bark compounds to replace environmentally harmful ingredients in products from cosmetics to pharmaceuticals, raised €5M in funding.
The round was led by Metsä Spring with participation from Innovestor and angel investors. The round was completed with grants and loans from Business Finland as well as other public financing sources.
The company intends to use the funds to set up a pilot plant in Kokkola, which will be used to test and plan the process for the next industrial-scale plant, capable of producing 20 tonnes of birch bark products per year by 2023, to conduct R&D work, as well as to grow their existing customer base in international markets.
Led by Sami Selkälä, CEO and Founder, Innomost develops and produces high-value bioactive ingredients from forest industry side streams that enable customers to make innovations in the cosmetic beauty industry. Its current product portfolio consists of birch charcoal powder, birch bark powder, betulin, suberin and azelaic acid, which can trigger innovation in all cosmetic product categories including skincare, haircare, body care, decorative cosmetics, and oral care.
Innomost Raises €5M in Funding
Innomost, a Helsinki, Finland-based startup that upcycles valuable birch bark compounds to replace environmentally harmful ingredients in products from cosmetics to pharmaceuticals, raised €5M in funding
Cricket Health Raises $83.5M in Series B Funding
Cricket Health, a San Francisco, CA- and Cambridge, MA-based provider of value-based kidney care, closed an $83.5m Series B funding round.
The round was led by Valtruis with participation from existing investors Oak HC/FT and Cigna Ventures, as well as K2 HealthVentures and a strategic investment from Blue Shield of California.
The company intends to use the funds for rapid expansion to support demand for its care model for people with kidney disease across the United States.
Founded in 2015 and led by Robert Sepucha, CEO, Cricket Health is a provider of value-based kidney care with a clinically-proven approach to managing chronic kidney disease (CKD) and end-stage kidney disease (ESKD).
Cricket Health Raises $83.5M in Series B Funding
Cricket Health, a San Francisco, CA- and Cambridge, MA-based provider of value-based kidney care, closed an $83.5m Series B funding round
Engrail Therapeutics Raises $32M Extension in Series A
Engrail Therapeutics, a San Diego, CA-based neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies, raised a $32m extension of Series A financing, which brings the total round to $64m.
Nan Fung Life Sciences (NFLS), the global investment platform of the Nan Fung Group, led this round following their leadership of the original Series A raise.
The company will use the proceeds to finance the advancement of their diverse pipeline, including its lead assets, ENX-101, ENX-102 and internal preclinical programs.
Led by Vikram Sudarsan, Ph.D., CEO and president, Engrail Therapeutics has assembled a diverse portfolio of assets with validated mechanisms through its dynamic model for advancing drugs aimed at treating life-limiting diseases of the nervous system. By adopting a ‘science-first’ approach, combined with a comprehensive view of clinical development strategy, regulatory considerations and intellectual property, the company can find differentiated assets with validated mechanisms of action for diseases where significant patient need still exists.
Engrail Therapeutics Raises $32M Extension in Series A
Engrail Therapeutics, a San Diego, CA-based neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies, raised a $32m extension of Series A financing, which brings the total round to $64m.
Aardvark Therapeutics Closes $29M Series B Funding
Aardvark Therapeutics, Inc., a San Diego, CA-based clinical stage biopharmaceutical company, completed a $29m Series B financing.
The round was led by Sorrento Therapeutics with participation from existing investors including Vickers Venture Partners, Premier Partners, BNH Investment, and Korea Omega. The Foundation for Prader-Willi Research also participated as an investor in the Series B.
Led by CEO, Tien Lee, M.D., Aardvark Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Aardvark Therapeutics Closes $29M Series B Funding
Aardvark Therapeutics, Inc., a San Diego, CA-based clinical stage biopharmaceutical company, completed a $29m Series B financing
Berry Oncology Closes US$99.15M Series B1 Funding
Berry Oncology Corporation, a member company of China’s leading early cancer screening firm Berry Genomics, closed a US$99.15m Series B1 financing round.
This round was led by China Merchants Capital Management Co., Ltd. Existing investors Qiming Venture Partners and Legend Capital, along with new investors including Zhongjin Qichen Industry Equity Investment Fund, E Fund, Fujian Venture Investment Management Co., Ltd., Xiamen C&D Emerging Industry Equity Investment Co., Ltd. and other investors also participated.
The new proceeds will enable the company to meet the demand for early cancer screening and diagnosis and boost its expansion in the market.
Established in August 2017 and led by Zhou Jun, CEO, Berry Oncology leverages technology, business channels and capital of its predecessor Berry Genomics, a leader in genetics research, to complete genetic testing product service system for high-risk populations and patients of cancers. Up till now, it has been working with over 700 hospitals in China and has provided genetic testing of cancers for hundreds of thousands of cancer patients.
Berry Oncology Closes US$99.15M Series B1 Funding
Berry Oncology Corporation, a member company of China’s leading early cancer screening firm Berry Genomics, closed a US$99.15m Series B1 financing round
Zentera Therapeutics Raises $75M in Series b Funding
Zentera Therapeutics, a Shanghai, China-based clinical-stage biopharmaceutical company, raised $75M in Series B funding.
The round was led by OrbiMed Advisors Asia and Tybourne Capital Management with participation from Avidity Partners, Casdin Capital, Surveyor Capital, Farallon Capital Management, Lilly Asia Ventures, Logos Capital, Perceptive Advisors, Redmile Group and Viking Global Investors.
The company intends to use the funds to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China.
Formed by Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) to develop cancer therapies in China, Zentera Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics. Led by CEO Dr. Anthony Sun, who is also the Chairman and Chief Executive Officer at Zentalis, the company is developing a broad pipeline of oncology candidates, including Zentalis-discovered ZN-c3, a WEE1 inhibitor, ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, and ZN-d5, a BCL-2 inhibitor. Zentera has operations in both Shanghai and Beijing.
